PDF herunterladen
Int J Angiol 2017; 26(01): 001-011
DOI: 10.1055/s-0037-1598183
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?

Kailash Prasad
1   Department of Physiology, College of Medicine, University of Saskatchewan, Saskatchewan, Canada
,
Manish Mishra
1   Department of Physiology, College of Medicine, University of Saskatchewan, Saskatchewan, Canada
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
03. Februar 2017 (online)

   Lizenzen und Reprints

Abstract

There is a close relationship between arterial stiffness and blood pressure. The studies suggest that the advanced glycation end products (AGEs) and its cell receptor (RAGE) are involved in the arterial stiffness in two ways: changes in arterial structure and vascular function. Plasma levels of AGEs and expression of RAGE are elevated, while the levels of soluble RAGE (sRAGE) and endogenous secretory RAGE (esRAGE) are lowered in patients with hypertension (HTN). There is a positive correlation between plasma levels of AGEs and arterial stiffness, and an inverse association between arterial stiffness/HTN, and serum levels of sRAGE and esRAGE. Various measures can reduce the levels of AGEs and expression of RAGE, and elevate sRAGE. Arterial stiffness and blood pressure could be reduced by lowering the serum levels of AGEs, and increasing the levels of sRAGE. Levels of AGEs can be lowered by reducing the consumption of AGE-rich diet, short duration of cooking in moist heat at low temperature, and cessation of cigarette smoking. Drugs such as aminoguanidine, vitamins, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II receptor blockers, statins, and metformin inhibit AGE formation. Alagebrium, an AGE breakers reduces levels of AGEs. Clinical trials with some drugs tend to reduce stiffness. Systemic administration of sRAGE has beneficial effect in animal studies. In conclusion, AGE–RAGE axis is involved in arterial stiffness and HTN. The studies suggest that inhibition of AGEs formation, reduction of AGE consumption, blockade of AGE–RAGE interaction, suppression of RAGE expression, and exogenous administration of sRAGE may be novel therapeutic strategies for treatment of arterial stiffness and HTN.

Keywords

advanced glycation end products - receptor for AGE - soluble receptor for AGE - hypertension - arterial stiffness - management of hypertension
 

  • References

  • 1 Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22 (1) 11-19
    CrossrefPubMedGoogle Scholar
  • 2 Wendt T, Tanji N, Guo J , et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003; 14 (5) 1383-1395
    CrossrefPubMedGoogle Scholar
  • 3 Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84 (5) 489-497
    CrossrefPubMedGoogle Scholar
  • 4 Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000; 1498 (02/03) 99-111
    CrossrefPubMedGoogle Scholar
  • 5 Prasad K. Hypertension. In: Dieter RS, Dieter Jr. RA, Dieter III RA, , eds. Peripheral Arterial Disease. New York, NY: The McGraw-Hill Company, INC; 2009: 125-140
    Google Scholar
  • 6 Prasad K. Blood pressure regulation. In: Dieter RS, Dieter Jr. RA, Dieter III RA, , eds. Peripheral Arterial Disease. New York, NY: The McGraw-Hill Company, INC; 2009: 113-123
    Google Scholar
  • 7 Franklin SS, Gustin IV W, Wong ND , et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96 (1) 308-315
    CrossrefPubMedGoogle Scholar
  • 8 Greenwald SE. Ageing of the conduit arteries. J Pathol 2007; 211 (2) 157-172
    CrossrefPubMedGoogle Scholar
  • 9 Arnett DK. Arterial stiffness and hypertension. Available at: http://www.fac.org.ar/scvc/llave/hbp/arnett/arnetti.htm
    PubMedGoogle Scholar
  • 10 Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25 (5) 932-943
    CrossrefPubMedGoogle Scholar
  • 11 Dart AM, Kingwell BA. Pulse pressure--a review of mechanisms and clinical relevance. J Am Coll Cardiol 2001; 37 (4) 975-984
    CrossrefPubMedGoogle Scholar
  • 12 Jacob MP. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed Pharmacother 2003; 57 (05/06) 195-202
    CrossrefPubMedGoogle Scholar
  • 13 Hope SA, Hughes AD. Drug effects on the mechanical properties of large arteries in humans. Clin Exp Pharmacol Physiol 2007; 34 (7) 688-693
    CrossrefPubMedGoogle Scholar
  • 14 Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension 2005; 45 (6) 1050-1055
    CrossrefPubMedGoogle Scholar
  • 15 Lewington S, Clarke R, Qizilbash N, Peto R, Collins R ; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360 (9349): 1903-1913
    CrossrefPubMedGoogle Scholar
  • 16 Matz RL, Schott C, Stoclet JC, Andriantsitohaina R. Age-related endothelial dysfunction with respect to nitric oxide, endothelium-derived hyperpolarizing factor and cyclooxygenase products. Physiol Res 2000; 49 (1) 11-18
    PubMedGoogle Scholar
  • 17 Dzau VJ. Significance of the vascular renin-angiotensin pathway. Hypertension 1986; 8 (7) 553-559
    CrossrefPubMedGoogle Scholar
  • 18 Prasad K. Oxyradicals as a mechanism of angiotensin-induced hypertension. Int J Angiol 2004; 13: 59-66
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 19 Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002; 106 (22) 2848-2853
    CrossrefPubMedGoogle Scholar
  • 20 Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 2003; 25 (03/04) 275-281
    CrossrefPubMedGoogle Scholar
  • 21 Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998; 37 (3) 586-600
    CrossrefPubMedGoogle Scholar
  • 22 Tam XH, Shiu SW, Leng L, Bucala R, Betteridge DJ, Tan KC. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in type 2 diabetes. Clin Sci (Lond) 2011; 120 (2) 81-89
    CrossrefPubMedGoogle Scholar
  • 23 Yonekura H, Yamamoto Y, Sakurai S , et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370 (Pt 3): 1097-1109
    CrossrefPubMedGoogle Scholar
  • 24 Koyama H, Shoji T, Yokoyama H , et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25 (12) 2587-2593
    CrossrefPubMedGoogle Scholar
  • 25 Prasad K, Dhar I, Zhou Q, Elmoselhi H, Shoker M, Shoker A. AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease. Mol Cell Biochem 2016; 423 (01/02) 105-114
    CrossrefPubMedGoogle Scholar
  • 26 Prasad K. Soluble receptor for advanced glycation end products (sRAGE) and cardiovascular disease. Int J Angiol 2006; 15: 57-68
    PubMedGoogle Scholar
  • 27 Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006; 13 (17) 1971-1978
    CrossrefPubMedGoogle Scholar
  • 28 Cooper ME. Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am J Hypertens 2004; 17 (12 Pt 2): 31S-38S
    CrossrefPubMedGoogle Scholar
  • 29 Mallipattu SK, He JC, Uribarri J. Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients. Semin Dial 2012; 25 (5) 529-538
    CrossrefPubMedGoogle Scholar
  • 30 Prasad K, Tiwari S. Therapeutic interventions for advanced glycation-end products and its receptor-mediated cardiovascular disease. Curr Pharm Des 2016; . PubMed: 27719648
    PubMedGoogle Scholar
  • 31 Prasad K, Dhar I, Caspar-Bell G. Role of advanced glycation end products and its receptors in the pathogenesis of cigarette smoke-induced cardiovascular disease. Int J Angiol 2015; 24 (2) 75-80
    PubMedGoogle Scholar
  • 32 Schmidt AM, Hasu M, Popov D , et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A 1994; 91 (19) 8807-8811
    CrossrefPubMedGoogle Scholar
  • 33 Schmidt AM, Hori O, Chen JX , et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96 (3) 1395-1403
    CrossrefPubMedGoogle Scholar
  • 34 Tanaka S, Avigad G, Brodsky B, Eikenberry EF. Glycation induces expansion of the molecular packing of collagen. J Mol Biol 1988; 203 (2) 495-505
    CrossrefPubMedGoogle Scholar
  • 35 Striker LJ, Striker GE. Administration of AGEs in vivo induces extracellular matrix gene expression. Nephrol Dial Transplant 1996; 11 (Suppl. 05) 62-65
    PubMedGoogle Scholar
  • 36 Reiser K, McCormick RJ, Rucker RB. Enzymatic and nonenzymatic cross-linking of collagen and elastin. FASEB J 1992; 6 (7) 2439-2449
    CrossrefPubMedGoogle Scholar
  • 37 Hogan M, Cerami A, Bucala R. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest 1992; 90 (3) 1110-1115
    CrossrefPubMedGoogle Scholar
  • 38 Rojas A, Romay S, González D, Herrera B, Delgado R, Otero K. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. Circ Res 2000; 86 (3) E50-E54
    CrossrefPubMedGoogle Scholar
  • 39 Xu B, Chibber R, Ruggiero D, Kohner E, Ritter J, Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 2003; 17 (10) 1289-1291
    CrossrefPubMedGoogle Scholar
  • 40 Goldin A, Beckman JA, Schmidt AM, Creager MA , et al. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114 (6) 597-605
    CrossrefPubMedGoogle Scholar
  • 41 Yamagishi S, Fujimori H, Yonekura H, Yamamoto Y, Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 1998; 41 (12) 1435-1441
    CrossrefPubMedGoogle Scholar
  • 42 Quehenberger P, Bierhaus A, Fasching P , et al. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 2000; 49 (9) 1561-1570
    CrossrefPubMedGoogle Scholar
  • 43 Yamazaki KG, Gonzalez E, Zambon AC. Crosstalk between the renin-angiotensin system and the advance glycation end product axis in the heart: role of the cardiac fibroblast. J Cardiovasc Transl Res 2012; 5 (6) 805-813
    CrossrefPubMedGoogle Scholar
  • 44 Hayashi A, Ryu A, Suzuki T, Kawada A, Tajima S. In vitro degradation of tropoelastin by reactive oxygen species. Arch Dermatol Res 1998; 290 (9) 497-500
    CrossrefPubMedGoogle Scholar
  • 45 Akhtar K, Broekelmann TJ, Miao M , et al. Oxidative and nitrosative modifications of tropoelastin prevent elastic fiber assembly in vitro. J Biol Chem 2010; 285 (48) 37396-37404
    CrossrefPubMedGoogle Scholar
  • 46 Bharadwaj LA, Prasad K. Mechanism of superoxide anion-induced modulation of vascular tone. Int J Angiol 2002; 11: 23-29
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 47 Bharadwaj L, Prasad K. Mediation of H2O2-induced vascular relaxation by endothelium-derived relaxing factor. Mol Cell Biochem 1995; 149/150: 267-270
    CrossrefPubMedGoogle Scholar
  • 48 Prasad K, Kalra J, Chaudhary AK, Debnath D. Effect of polymorphonuclear leukocyte-derived oxygen free radicals and hypochlorous acid on cardiac function and some biochemical parameters. Am Heart J 1990; 119 (3 Pt 1): 538-550
    CrossrefPubMedGoogle Scholar
  • 49 Prasad K, Kalra J, Chan WP, Chaudhary AK. Effect of oxygen free radicals on cardiovascular function at organ and cellular levels. Am Heart J 1989; 117 (6) 1196-1202
    CrossrefPubMedGoogle Scholar
  • 50 Liu Q, Chen HB, Luo M, Zheng H. Serum soluble RAGE level inversely correlates with left ventricular hypertrophy in essential hypertension patients. Genet Mol Res 2016; 15 (2) 15
    PubMedGoogle Scholar
  • 51 Nielsen WB, Vestbo J, Jensen GB. Isolated systolic hypertension as a major risk factor for stroke and myocardial infarction and an unexploited source of cardiovascular prevention: a prospective population-based study. J Hum Hypertens 1995; 9 (3) 175-180
    PubMedGoogle Scholar
  • 52 Wang X, Desai K, Clausen JT, Wu L. Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. Kidney Int 2004; 66 (6) 2315-2321
    CrossrefPubMedGoogle Scholar
  • 53 McNulty M, Mahmud A, Feely J. Advanced glycation end-products and arterial stiffness in hypertension. Am J Hypertens 2007; 20 (3) 242-247
    CrossrefPubMedGoogle Scholar
  • 54 Mayer O, Seidlerová J, Filipovský J, Wohlfahrt P, Cífková R. 7c.06: Soluble receptor for advanced glycation end-products and increased aortic stiffness in a general population. J Hypertens 2015; 33 (Suppl. 01) e97-e98
    PubMedGoogle Scholar
  • 55 Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 2001; 38 (4, suppl 1): S100-S106
    CrossrefPubMedGoogle Scholar
  • 56 Geroldi D, Falcone C, Emanuele E , et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005; 23 (9) 1725-1729
    CrossrefPubMedGoogle Scholar
  • 57 Koyama H, Yamamoto H, Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med 2007; 13 (11/12) 625-635
    CrossrefPubMedGoogle Scholar
  • 58 Semba RD, Najjar SS, Sun K, Lakatta EG, Ferrucci L. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens 2009; 22 (1) 74-79
    CrossrefPubMedGoogle Scholar
  • 59 Semba RD, Sun K, Schwartz AV , et al; Health ABC Study. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with arterial stiffness in older adults. J Hypertens 2015; 33 (4) 797-803 , discussion 803
    CrossrefPubMedGoogle Scholar
  • 60 Llauradó G, Ceperuelo-Mallafré V, Vilardell C , et al. Advanced glycation end products are associated with arterial stiffness in type 1 diabetes. J Endocrinol 2014; 221 (3) 405-413
    CrossrefPubMedGoogle Scholar
  • 61 Sourris KC, Lyons JG, Dougherty SL , et al. Plasma advanced glycation end products (AGEs) and NF-κB activity are independent determinants of diastolic and pulse pressure. Clin Chem Lab Med 2014; 52 (1) 129-138
    PubMedGoogle Scholar
  • 62 Huang QF, Sheng CS, Liu M, Li FH, Li Y, Wang JG. Arterial stiffness and wave reflections in relation to plasma advanced glycation end products in a Chinese population. Am J Hypertens 2013; 26 (6) 754-761
    CrossrefPubMedGoogle Scholar
  • 63 Won KB, Chang HJ, Park SH, Hong SY, Jang Y, Chung N. High serum advanced glycation end-products predict coronary artery disease irrespective of arterial stiffness in diabetic patients. Korean Circ J 2012; 42 (5) 335-340
    CrossrefPubMedGoogle Scholar
  • 64 Dimitriadis K, Tsioufis C, Kasiakogias A , et al. Soluble receptor for advanced glycation end-product levels are related to albuminuria and arterial stiffness in essential hypertension. Nutr Metab Cardiovasc Dis 2013; 23 (4) 382-388
    CrossrefPubMedGoogle Scholar
  • 65 Yeoh K, Liu J, Yeoh L , et al. Soluble receptor for advanced glycation end products (sRAGE) is associated with arterial stiffness only in normoalbuminuric type 2 diabetes. Cardiometabolic Risk & Vascular Biology. The Endocrine Society's 95th Annual Meeting and Expo, San Francisco, June 15–18, 2013 , presentation no. SUN-766 (Abstract)
    PubMedGoogle Scholar
  • 66 Yoon SJ, Park S, Park C , et al. Association of soluble receptor for advanced glycation end-product with increasing central aortic stiffness in hypertensive patients. Coron Artery Dis 2012; 23 (2) 85-90
    CrossrefPubMedGoogle Scholar
  • 67 Berg TJ, Clausen JT, Torjesen PA, Dahl-Jørgensen K, Bangstad HJ, Hanssen KF. The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care 1998; 21 (11) 1997-2002
    CrossrefPubMedGoogle Scholar
  • 68 Sharp PS, Rainbow S, Mukherjee S. Serum levels of low molecular weight advanced glycation end products in diabetic subjects. Diabet Med 2003; 20 (7) 575-579
    CrossrefPubMedGoogle Scholar
  • 69 Thomas MC, Söderlund J, Lehto M , et al; FinnDiane Study Group. Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia 2011; 54 (10) 2669-2677
    CrossrefPubMedGoogle Scholar
  • 70 Fujisawa K, Katakami N, Kaneto H , et al. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis 2013; 227 (2) 425-428
    CrossrefPubMedGoogle Scholar
  • 71 Prasad K. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality. Int J Angiol 2014; 23 (1) 11-16
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 72 Ghanayem N, Abdel Aziz W, El-Ghobashi Y , et al. Endogenous secretory receptor of advanced glycated end products of type II diabetic and hypertensive patients. Menoufia Med J 2014; 27: 395-400
    CrossrefPubMedGoogle Scholar
  • 73 Humpert PM, Djuric Z, Kopf S , et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 2007; 6: 9
    CrossrefPubMedGoogle Scholar
  • 74 Choi KM, Yoo HJ, Kim HY , et al. Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. Int J Cardiol 2009; 132 (1) 96-101
    CrossrefPubMedGoogle Scholar
  • 75 Di Pino A, Urbano F, Zagami RM , et al. Low endogenous secretory receptor for advanced glycation end-products levels are associated with inflammation and carotid atherosclerosis in prediabetes. J Clin Endocrinol Metab 2016; 101 (4) 1701-1709
    CrossrefPubMedGoogle Scholar
  • 76 Liao D, Arnett DK, Tyroler HA , et al. Arterial stiffness and the development of hypertension. The ARIC study. Hypertension 1999; 34 (2) 201-206
    Google Scholar
  • 77 Dernellis J, Panaretou M. Aortic stiffness is an independent predictor of progression to hypertension in nonhypertensive subjects. Hypertension 2005; 45 (3) 426-431
    CrossrefPubMedGoogle Scholar
  • 78 Weisenberger J. Foods High in AGEs. Available at: http://wwwdiabetesforecastorg/2014/11-nov/foods-high-in-ageshtml . Accessed 2014
    PubMedGoogle Scholar
  • 79 Uribarri J, Woodruff S, Goodman S , et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010; 110 (6) 911-16.e12
    CrossrefPubMedGoogle Scholar
  • 80 Koschinsky T, He CJ, Mitsuhashi T , et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 1997; 94 (12) 6474-6479
    CrossrefPubMedGoogle Scholar
  • 81 Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 2005; 1043: 461-466
    CrossrefPubMedGoogle Scholar
  • 82 Lin RY, Choudhury RP, Cai W , et al. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2003; 168 (2) 213-220
    CrossrefPubMedGoogle Scholar
  • 83 Ramful D, Tarnus E, Rondeau P, Da Silva CR, Bahorun T, Bourdon E. Citrus fruit extracts reduce advanced glycation end products (AGEs)- and H2O2-induced oxidative stress in human adipocytes. J Agric Food Chem 2010; 58 (20) 11119-11129
    CrossrefPubMedGoogle Scholar
  • 84 Liu W, Ma H, Frost L, Yuan T, Dain JA, Seeram NP. Pomegranate phenolics inhibit formation of advanced glycation endproducts by scavenging reactive carbonyl species. Food Funct 2014; 5 (11) 2996-3004
    CrossrefPubMedGoogle Scholar
  • 85 Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232 (4758): 1629-1632
    CrossrefPubMedGoogle Scholar
  • 86 Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 1994; 37 (1) 32-35
    CrossrefPubMedGoogle Scholar
  • 87 Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 1995; 26 (6) 875-888
    CrossrefPubMedGoogle Scholar
  • 88 Bolton WK, Cattran DC, Williams ME , et al; ACTION I Investigator Group. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004; 24 (1) 32-40
    CrossrefPubMedGoogle Scholar
  • 89 Whitter F, Spinowitz B, Wuerth JP. Pimagedine safety profile in patients with type-1 diabetes. J Am Soc Nephrol 1999; 10: 184A (Abstract)
    PubMedGoogle Scholar
  • 90 Metz TO, Alderson NL, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys 2003; 419 (1) 41-49
    CrossrefPubMedGoogle Scholar
  • 91 Hammes HP, Du X, Edelstein D , et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9 (3) 294-299
    CrossrefPubMedGoogle Scholar
  • 92 Subratty AH, Aukburally N, Jowaheer V , et al. Vitamin C and urea inhibit the formation of advanced glycation end products in vitro. Nutr Food Sci 2010; 40: 456-465
    CrossrefPubMedGoogle Scholar
  • 93 Salum E, Kals J, Kampus P , et al. Vitamin D reduces deposition of advanced glycation end-products in the aortic wall and systemic oxidative stress in diabetic rats. Diabetes Res Clin Pract 2013; 100 (2) 243-249
    Google Scholar
  • 94 Baragetti I, Furiani S, Vettoretti S , et al. Role of vitamin E-coated membrane in reducing advanced glycation end products in hemodialysis patients: a pilot study. Blood Purif 2006; 24 (4) 369-376
    CrossrefPubMedGoogle Scholar
  • 95 Weng S, Sprague JE, Oh J. Vitamin D deficiency induces high blood pressure and accelerates atherosclerosis in mice. Plos One 2013; 8 (1) e54625
    CrossrefPubMedGoogle Scholar
  • 96 Sebeková K, Gazdíková K, Syrová D , et al. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J Hum Hypertens 2003; 17 (4) 265-270
    CrossrefPubMedGoogle Scholar
  • 97 Yoshida T, Yamagishi S, Matsui T , et al. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 2008; 36 (2) 237-243
    CrossrefPubMedGoogle Scholar
  • 98 Komiya N, Hirose H, Saisho Y, Saito I, Itoh H. Effects of 12-month valsartan therapy on glycation and oxidative stress markers in type 2 diabetic subjects with hypertension. Int Heart J 2008; 49 (6) 681-689
    CrossrefPubMedGoogle Scholar
  • 99 Saha SA, LaSalle BK, Clifton GD, Short RA, Tuttle KR. Modulation of advanced glycation end products by candesartan in patients with diabetic kidney disease--a dose-response relationship study. Am J Ther 2010; 17 (6) 553-558
    CrossrefPubMedGoogle Scholar
  • 100 Scharnagl H, Stojakovic T, Winkler K, Rosinger S, März W, Boehm BO. The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2007; 115 (6) 372-375
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 101 Nozue T, Yamagish S, Takeuchi M , et al. Effect of statins on the serum soluble form of receptor for advanced glycation end-products and its association with coronary atherosclerosis in patients with angina pectoris. IJC Metab Endocr 2014; 4: 47-52
    PubMedGoogle Scholar
  • 102 Diamanti-Kandarakis E, Alexandraki K, Piperi C , et al. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. Metabolism 2007; 56 (1) 129-134
    CrossrefPubMedGoogle Scholar
  • 103 Abdul HM, Butterfield DA. Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-L-carnitine and alpha-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. Free Radic Biol Med 2007; 42 (3) 371-384
    CrossrefPubMedGoogle Scholar
  • 104 Nandhini AT, Thirunavukkarasu V, Anuradha CV. Taurine prevents collagen abnormalities in high fructose-fed rats. Indian J Med Res 2005; 122 (2) 171-177
    PubMedGoogle Scholar
  • 105 Urios P, Grigorova-Borsos AM, Sternberg M. Aspirin inhibits the formation of pentosidine, a cross-linking advanced glycation end product, in collagen. Diabetes Res Clin Pract 2007; 77 (2) 337-340
    CrossrefPubMedGoogle Scholar
  • 106 Rahbar S, Natrajan R, Yerneni K, Scott S, Gonzales N, Nadler JL. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 2000; 301 (1-2): 65-77
    CrossrefPubMedGoogle Scholar
  • 107 Mizutani K, Ikeda K, Yamori Y. Resveratrol inhibits AGEs-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochem Biophys Res Commun 2000; 274 (1) 61-67
    CrossrefPubMedGoogle Scholar
  • 108 Tang Y, Chen A. Curcumin eliminates the effect of advanced glycation end-products (AGEs) on the divergent regulation of gene expression of receptors of AGEs by interrupting leptin signaling. Lab Invest 2014; 94 (5) 503-516
    CrossrefPubMedGoogle Scholar
  • 109 Vasan S, Zhang X, Zhang X , et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996; 382 (6588): 275-278
    CrossrefPubMedGoogle Scholar
  • 110 Wolffenbuttel BH, Boulanger CM, Crijns FR , et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 1998; 95 (8) 4630-4634
    CrossrefPubMedGoogle Scholar
  • 111 Vaitkevicius PV, Lane M, Spurgeon H , et al. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci U S A 2001; 98 (3) 1171-1175
    CrossrefPubMedGoogle Scholar
  • 112 Kass DA, Shapiro EP, Kawaguchi M , et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104 (13) 1464-1470
    CrossrefPubMedGoogle Scholar
  • 113 Bakris GL, Bank AJ, Kass DA, Neutel JM, Preston RA, Oparil S. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 2004; 17 (12 Pt 2): 23S-30S
    PubMedGoogle Scholar
  • 114 Cuccurullo C, Iezzi A, Fazia ML , et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006; 26 (12) 2716-2723
    CrossrefPubMedGoogle Scholar
  • 115 Xu L, Zang P, Feng B, Qian Q. Atorvastatin inhibits the expression of RAGE induced by advanced glycation end products on aortas in healthy Sprague-Dawley rats. Diabetol Metab Syndr 2014; 6 (1) 102
    CrossrefPubMedGoogle Scholar
  • 116 Nakamura K, Yamagishi S, Nakamura Y , et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 2005; 70 (3) 137-141
    CrossrefPubMedGoogle Scholar
  • 117 Fan Q, Liao J, Kobayashi M , et al. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004; 19 (12) 3012-3020
    CrossrefPubMedGoogle Scholar
  • 118 Marx N, Walcher D, Ivanova N , et al. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 2004; 53 (10) 2662-2668
    CrossrefPubMedGoogle Scholar
  • 119 Lin J, Tang Y, Kang Q, Feng Y, Chen A. Curcumin inhibits gene expression of receptor for advanced glycation end-products (RAGE) in hepatic stellate cells in vitro by elevating PPARγ activity and attenuating oxidative stress. Br J Pharmacol 2012; 166 (8) 2212-2227
    CrossrefPubMedGoogle Scholar
  • 120 Yamagishi S, Takeuchi M. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. Drugs Exp Clin Res 2004; 30 (4) 169-175
    PubMedGoogle Scholar
  • 121 Quade-Lyssy P, Kanarek AM, Baiersdörfer M, Postina R, Kojro E. Statins stimulate the production of a soluble form of the receptor for advanced glycation end products. J Lipid Res 2013; 54 (11) 3052-3061
    CrossrefPubMedGoogle Scholar
  • 122 Tam HL, Shiu SW, Wong Y, Chow WS, Betteridge DJ, Tan KC. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis 2010; 209 (1) 173-177
    CrossrefPubMedGoogle Scholar
  • 123 Forbes JM, Thorpe SR, Thallas-Bonke V , et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005; 16 (8) 2363-2372
    CrossrefPubMedGoogle Scholar
  • 124 Tan KC, Chow WS, Tso AW , et al. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia 2007; 50 (9) 1819-1825
    CrossrefPubMedGoogle Scholar
  • 125 Tang SC, Wang YC, Li YI , et al. Functional role of soluble receptor for advanced glycation end products in stroke. Arterioscler Thromb Vasc Biol 2013; 33 (3) 585-594
    CrossrefPubMedGoogle Scholar
  • 126 Sakaguchi T, Yan SF, Yan SD , et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003; 111 (7) 959-972
    CrossrefPubMedGoogle Scholar
  • 127 Wautier JL, Zoukourian C, Chappey O , et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97 (1) 238-243
    CrossrefPubMedGoogle Scholar
  • 128 Park L, Raman KG, Lee KJ , et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4 (9) 1025-1031
    CrossrefPubMedGoogle Scholar
  • 129 Kanaki AI, Sarafidis PA, Georgianos PI , et al. Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am J Hypertens 2013; 26 (5) 608-616
    CrossrefPubMedGoogle Scholar
  • 130 Tousoulis D, Oikonomou E, Siasos G , et al. Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure. Atherosclerosis 2013; 227 (2) 367-372
    CrossrefPubMedGoogle Scholar
  • 131 Rizos EC, Agouridis AP, Elisaf MS. The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. Curr Vasc Pharmacol 2010; 8 (5) 638-644
    CrossrefPubMedGoogle Scholar
  • 132 Harashima K, Hayashi J, Miwa T, Tsunoda T. Long-term pioglitazone therapy improves arterial stiffness in patients with type 2 diabetes mellitus. Metabolism 2009; 58 (6) 739-745
    CrossrefPubMedGoogle Scholar
  • 133 Kiyici S, Ersoy C, Kaderli A , et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Res Clin Pract 2009; 86 (1) 44-50
    CrossrefPubMedGoogle Scholar
  • 134 Chan DT, Watts GF, Irish AB, Dogra GK. Rosiglitazone does not improve vascular function in subjects with chronic kidney disease. Nephrol Dial Transplant 2011; 26 (11) 3543-3549
    CrossrefPubMedGoogle Scholar
  • 135 Agarwal N, Rice SP, Bolusani H , et al. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 2010; 95 (2) 722-730
    CrossrefPubMedGoogle Scholar
  • 136 Cantini C, Kieffer P, Corman B, Limiñana P, Atkinson J, Lartaud-Idjouadiene I. Aminoguanidine and aortic wall mechanics, structure, and composition in aged rats. Hypertension 2001; 38 (4) 943-948
    CrossrefPubMedGoogle Scholar
  • 137 Chang KC, Hsu KL, Tseng CD, Lin YD, Cho YL, Tseng YZ. Aminoguanidine prevents arterial stiffening and cardiac hypertrophy in streptozotocin-induced diabetes in rats. Br J Pharmacol 2006; 147 (8) 944-950
    CrossrefPubMedGoogle Scholar
  • 138 Corman B, Duriez M, Poitevin P , et al. Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc Natl Acad Sci U S A 1998; 95 (3) 1301-1306
    CrossrefPubMedGoogle Scholar
  • 139 Steppan J, Tran H, Benjo AM , et al. Alagebrium in combination with exercise ameliorates age-associated ventricular and vascular stiffness. Exp Gerontol 2012; 47 (8) 565-572
    CrossrefPubMedGoogle Scholar
  • 140 Kaess BM, Rong J, Larson MG , et al. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA 2012; 308 (9) 875-881
    CrossrefPubMedGoogle Scholar
  • 141 Sutton-Tyrrell K, Newman A, Simonsick EM , et al. Aortic stiffness is associated with visceral adiposity in older adults enrolled in the study of health, aging, and body composition. Hypertension 2001; 38 (3) 429-433
    CrossrefPubMedGoogle Scholar
  • 142 Mitchell GF, Guo CY, Benjamin EJ , et al. Cross-sectional correlates of increased aortic stiffness in the community: the Framingham Heart Study. Circulation 2007; 115 (20) 2628-2636
    CrossrefPubMedGoogle Scholar
  • 143 Mancia G, De Backer G, Dominiczak A , et al; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25 (6) 1105-1187
    CrossrefPubMedGoogle Scholar
  • 144 Messerli FH, Frohlich ED, Ventura HO. Arterial compliance in essential hypertension. J Cardiovasc Pharmacol 1985; 7 (Suppl. 02) S33-S35
    PubMedGoogle Scholar